Pancreatic Cancer Research

ResearcherUniversidad Rey Juan CarlosActive in the last 2 years

Javier Martínez‐Useros

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9007-828X; OpenAlex author ID A5075463200. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 20

  1. Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study. Last author DOI 10.1093/ajcp/aqag037↗
  2. Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations. Last author DOI 10.3389/fphar.2026.1868595↗
  3. The crosstalk within tumor microenvironment and exosomes in pancreatic cancer. Last author DOI 10.1016/j.bbcan.2025.189308↗
  4. Blood circulating miRNAs as pancreatic cancer biomarkers: An evidence from pooled analysis and bioinformatics study. Last author DOI 10.1016/j.ijbiomac.2025.142469↗
  5. FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer Last author DOI 10.1101/2025.09.12.675778↗
  6. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  7. Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment. Last author DOI 10.3390/antiox13111405↗
  8. DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer. Last author DOI 10.3390/biomedicines11102812↗
  9. Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms241914979↗
  10. A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. Last author DOI 10.3390/jcm11247310↗
  11. The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. Co-author DOI 10.3390/cancers13020322↗
  12. The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. First author DOI 10.3390/jcm9051252↗
  13. Still a place for conventional histopathological analysis in the era of molecular medicine: predicting prognosis of resectable ductal pancreatic adenocarcinoma. First author DOI 10.1007/s12094-018-02008-4↗
  14. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Co-author DOI 10.1007/s12253-017-0341-0↗
  15. The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. First author DOI 10.3390/jcm8091275↗
  16. New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. Co-author DOI 10.3390/ijms19092468↗
  17. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. Co-author DOI 10.1371/journal.pone.0182044↗
  18. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. Co-author DOI 10.3390/jcm6030029↗
  19. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Co-author DOI 10.1155/2016/1869304↗
  20. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Co-author DOI 10.1155/2016/4873089↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jesús García‐Foncillas · 16 shared papers, 2016–2026 · strength 2.79
  2. Michael Ochieng’ Otieno · 6 shared papers, 2023–2025 · strength 1.61
  3. María Jesús Fernández‐Aceñero · 9 shared papers, 2017–2026 · strength 1.38
  4. Carlos Lacalle-González · 5 shared papers, 2023–2026 · strength 1.25
  5. Carlos Lopez-Blazquez · 3 shared papers, 2023–2025 · strength 0.73
  6. Weiyao Li · 7 shared papers, 2017–2022 · strength 0.71
  7. Tomasz Powrózek · 2 shared papers, 2025 · strength 0.69
  8. Alberto Orta · 3 shared papers, 2020–2026 · strength 0.58
  9. Nuria Garcia-Carbonero · 4 shared papers, 2018–2022 · strength 0.45
  10. Ana María Colino Gallardo · 1 shared paper, 2026 · strength 0.32
  11. Paula Iglesias-Matesanz · 1 shared paper, 2024 · strength 0.26
  12. Katja Peschke · 1 shared paper, 2025 · strength 0.16
  13. Katrin J. Frank · 1 shared paper, 2025 · strength 0.16
  14. Jiaoyu Ai · 1 shared paper, 2025 · strength 0.16
  15. Derya Bakırdöğen · 1 shared paper, 2025 · strength 0.16
  16. Marina Lesina · 1 shared paper, 2025 · strength 0.16
  17. Kıvanç Görgülü · 1 shared paper, 2025 · strength 0.16
  18. Nan Wu · 1 shared paper, 2025 · strength 0.16
  19. Sonia Alcalá · 1 shared paper, 2025 · strength 0.16
  20. Raphela A. Ranjan · 1 shared paper, 2025 · strength 0.16
  21. Maximilian Reichert · 1 shared paper, 2025 · strength 0.16
  22. Harun Öztürk · 1 shared paper, 2025 · strength 0.16
  23. Juan Carlos López-Gil · 1 shared paper, 2025 · strength 0.16
  24. Roland Michael Schmid · 1 shared paper, 2025 · strength 0.16
  25. Dietrich Alexander Ruess · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.